RedHill Biopharma Ltd. Statistics
Share Statistics
RedHill Biopharma Ltd. has 1.27M shares outstanding. The number of shares has increased by -95.71% in one year.
| Shares Outstanding | 1.27M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.27M |
| Failed to Deliver (FTD) Shares | 2.77K |
| FTD / Avg. Volume | 16.63% |
Short Selling Information
The latest short interest is 5.29K, so 0.41% of the outstanding shares have been sold short.
| Short Interest | 5.29K |
| Short % of Shares Out | 0.41% |
| Short % of Float | 0.42% |
| Short Ratio (days to cover) | 0.26 |
Valuation Ratios
The PE ratio is 9.89 and the forward PE ratio is 239.33.
| PE Ratio | 9.89 |
| Forward PE | 239.33 |
| PS Ratio | 36.3 |
| Forward PS | 0.1 |
| PB Ratio | 114.28 |
| P/FCF Ratio | -6.6 |
| PEG Ratio | n/a |
Enterprise Valuation
RedHill Biopharma Ltd. has an Enterprise Value (EV) of 4.27M.
| EV / Earnings | 0.18 |
| EV / Sales | 0.66 |
| EV / EBITDA | 0.16 |
| EV / EBIT | 0.34 |
| EV / FCF | -0.12 |
Financial Position
The company has a current ratio of 0.84, with a Debt / Equity ratio of 0.57.
| Current Ratio | 0.84 |
| Quick Ratio | 0.61 |
| Debt / Equity | 0.57 |
| Total Debt / Capitalization | 36.18 |
| Cash Flow / Debt | -30.54 |
| Interest Coverage | 34.42 |
Financial Efficiency
Return on equity (ROE) is 11.56% and return on capital (ROIC) is 389.64%.
| Return on Equity (ROE) | 11.56% |
| Return on Assets (ROA) | 1.04% |
| Return on Capital (ROIC) | 389.64% |
| Revenue Per Employee | 122.89K |
| Profits Per Employee | 451.25K |
| Employee Count | 53 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 0.79 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -80.68% in the last 52 weeks. The beta is 3.67, so RedHill Biopharma Ltd.'s price volatility has been higher than the market average.
| Beta | 3.67 |
| 52-Week Price Change | -80.68% |
| 50-Day Moving Average | 7.16 |
| 200-Day Moving Average | 9.41 |
| Relative Strength Index (RSI) | 32.14 |
| Average Volume (20 Days) | 16.67K |
Income Statement
In the last 12 months, RedHill Biopharma Ltd. had revenue of 6.51M and earned 23.92M in profits. Earnings per share was 3.69.
| Revenue | 6.51M |
| Gross Profit | 3.05M |
| Operating Income | 12.63M |
| Net Income | 23.92M |
| EBITDA | 26.31M |
| EBIT | 12.63M |
| Earnings Per Share (EPS) | 3.69 |
Balance Sheet
The company has 5.57M in cash and 1.17M in debt, giving a net cash position of 4.40M.
| Cash & Cash Equivalents | 5.57M |
| Total Debt | 1.17M |
| Net Cash | 4.40M |
| Retained Earnings | -407.74M |
| Total Assets | 35.04M |
| Working Capital | -1.14M |
Cash Flow
In the last 12 months, operating cash flow was -35.82M and capital expenditures -11.00K, giving a free cash flow of -35.83M.
| Operating Cash Flow | -35.82M |
| Capital Expenditures | -11.00K |
| Free Cash Flow | -35.83M |
| FCF Per Share | -5.53 |
Margins
Gross margin is 46.89%, with operating and profit margins of 193.95% and 367.19%.
| Gross Margin | 46.89% |
| Operating Margin | 193.95% |
| Pretax Margin | 367.75% |
| Profit Margin | 367.19% |
| EBITDA Margin | 403.94% |
| EBIT Margin | 193.95% |
| FCF Margin | -550.13% |
Dividends & Yields
RDHL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 68.21% |
| FCF Yield | -519.59% |
Analyst Forecast
Currently there are no analyst rating for RDHL.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Aug 20, 2024. It was a backward split with a ratio of 1:25.
| Last Split Date | Aug 20, 2024 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -9.73 |
| Piotroski F-Score | 2 |